|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08622 HUAKANG BIOMED
Nominal 
0.135 -0.033 (-19.643%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 24,629 | -2.767% | 25,330 | 26,127 | 21,967 | 25,471 |
| Cost of Sales | (8,536) | 1.426% | (8,416) | (9,671) | (7,249) | (7,580) |
| Gross Profit | 16,093 | -4.854% | 16,914 | 16,456 | 14,718 | 17,891 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | (2,556) | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | 7 | 39 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | (40) | 0 | |
| Profit / (Loss) before Taxation | (5,782) | 92.285% | (3,007) | (3,903) | (11,372) | 658 | |
| Taxation | 0 | -- | (68) | (317) | (255) | (942) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (5,782) | 88.033% | (3,075) | (4,220) | (11,627) | (284) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (351) | -0.847% | (354) | (77) | (111) | (102) |
| Depreciation & Amortisation | 3,179 | 1.242% | 3,140 | 2,949 | 3,194 | 2,762 |
| Directors' Emoluments | 2,743 | -8.292% | 2,991 | 2,453 | 3,844 | 1,232 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -1.390 | 82.895% | -0.760 | -1.060 | -2.910 | -0.070 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.000 | -- | 0.003 | (0.006) | (0.010) | (0.008) |
| NBV per share ($) | 0.122 | -- | 0.136 | 0.144 | 0.155 | 0.177 |
| Remarks: | Real time quote last updated: 24/12/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -1,779,000 |
| %Change | 22.268% |
| EPS / (LPS) | RMB -0.004 |
| NBV Per Share (¥) | RMB 0.113 |